Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Aventis Pasteur Live Recombinant ALVAC-HIV (vCP205, HIV-1 Env/Gag/Pol) in Seronegative Adults Administered (1) Subcutaneously Via Ex Vivo Transfected, Autologous Dendritic Cells, (2) Intradermally, or (3) Intramuscularly

NCT00013572 is registered in ClinicalTrials.gov with Walter Reed Army Institute of Research (WRAIR) as lead sponsor.

NCT NCT00013572
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00013572 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Aventis Pasteur Live Recombinant ALVAC-HIV (vCP205, HIV-1 Env/Gag/Pol) in Seronegative Adults Administered (1) Subcutaneously Via Ex Vivo Transfected, Autologous Dendritic Cells, (2) Intradermally, or (3) Intramuscularly
Lead sponsor
Walter Reed Army Institute of Research (WRAIR)
Phase
Phase 1
Overall status
Unknown status
Start date
Not reported
Completion date
Not reported
Enrollment
36
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections, hiv seronegativity